
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna has projected product sales of $1.73 billion in 2025, which are expected to grow to $2.15 billion in 2026, indicating a solid revenue growth trajectory. The company's recent $1.5 billion debt deal enhances its balance sheet flexibility, positioning it well to navigate uncertainties while capitalizing on future opportunities, alongside improvements in manufacturing efficiency that may increase gross margins by 10% over the next three years. Additionally, positive clinical trial results in diverse therapeutic areas, particularly in oncology, and the potential for continued advancements in its mRNA pipeline contribute to a favorable outlook for Moderna's stock performance.
Bears say
Moderna's stock outlook is negatively impacted by significant declines in revenue from COVID vaccine sales, which are projected to decrease from $18 billion in 2022 to $6.7 billion in 2023, with further reductions anticipated for 2025 due to waning vaccination rates. Additionally, competitive pressures from established RSV vaccines such as Arexvy and Abrysvo hinder the potential commercial success of their mRESVIA program, while the overall progress of their clinical pipeline remains slow in areas outside of respiratory vaccines. Furthermore, the ongoing uncertainty around EU sales negotiations has led to expectations of low sales figures for both 2024 and 2025, contributing to a downward revision of the company's enterprise value from $22.12 billion to $21.53 billion.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares